Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

advanced breast cancer

- PMLiVE

AstraZeneca adds cardiovascular resources to online diabetes programme

Expansion of Fit2Me also includes new Apple and Android mobile apps

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

NICE backs use of AZ’s Brilique as maintenance therapy

Drug to be used with asprin as treatment for heart attack patients

AstraZeneca AZ global R&D corporate HQ

AZ’s selumetinib stumbles at last fence in lung cancer

Phase III trial shows failure to improve patient survival rates

- PMLiVE

AstraZeneca embarks on oncology research access project

Invites companies to join molecular data resource consortium

- PMLiVE

Amgen enters into $540m immunotherapy collaboration

Acquires global rights to Advaxis’ preclinical oncology candidate ADXS-NEO

- PMLiVE

Keytruda cleared in Europe for lung cancer

New second-line indication for Merck’s drug puts it in direct competition with BMS’ Opdivo

- PMLiVE

Boehringer starts to feel impact of Spiriva generics

Asthma and COPD therapy facing increasing competition in ‘crowded’ market category

- PMLiVE

AZ feels Crestor sting but new products provide some relief

Tagrisso and Lynparza boost sales while a string of new cancer studies are in the pipeline

Brextinction

Evolution predicts tragic consequences from the UK's choice

- PMLiVE

Evolve or die

How brand teams can bring more value to their customers

Boehringer Ingelheim headquarters

Boehringer stops Gilotrif head and neck cancer trials

Trial data suggests the drug is “highly unlikely” to prolong patients’ remission

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links